Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Ajanta Pharma Ltd
Quarter-by-quarter operating performance
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 882 | 1,021 | 1,028 | 1,105 | 1,054 | 1,145 | 1,187 | 1,146 | 1,170 | 1,303 | 1,354 | 1,375 | 1,422 |
| Expenses + | 732 | 750 | 738 | 791 | 776 | 815 | 875 | 825 | 873 | 951 | 1,026 | 993 | 1,088 |
| Operating Profit | 149 | 271 | 291 | 314 | 278 | 330 | 311 | 321 | 297 | 351 | 328 | 382 | 333 |
| OPM % | 17% | 27% | 28% | 28% | 26% | 29% | 26% | 28% | 25% | 27% | 24% | 28% | 23% |
| Other Income + | 37 | 32 | 21 | 14 | 36 | 26 | 19 | 30 | 18 | 26 | 59 | 25 | 61 |
| Interest | 1 | 1 | 2 | 2 | 2 | 1 | 6 | 8 | 6 | 5 | 3 | 5 | 2 |
| Depreciation | 33 | 33 | 34 | 34 | 34 | 34 | 34 | 36 | 40 | 41 | 43 | 44 | 45 |
| Profit before tax | 152 | 269 | 276 | 291 | 278 | 322 | 290 | 307 | 269 | 331 | 341 | 359 | 347 |
| Tax % | 20% | 23% | 29% | 28% | 27% | 24% | 25% | 24% | 16% | 23% | 24% | 24% | 23% |
| Net Profit + | 122 | 208 | 195 | 210 | 203 | 246 | 216 | 233 | 225 | 255 | 260 | 274 | 267 |
| EPS in Rs | 9.54 | 16.24 | 15.24 | 16.39 | 15.82 | 19.68 | 17.33 | 18.64 | 18.03 | 20.44 | 20.83 | 21.91 | 21.35 |
Financials of Ajanta Pharma Ltd
Annual income statement trend
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 1,474 | 1,749 | 1,983 | 2,126 | 2,055 | 2,588 | 2,890 | 3,341 | 3,743 | 4,209 | 4,648 | 5,453 |
| Expenses + | 968 | 1,155 | 1,292 | 1,467 | 1,489 | 1,904 | 1,889 | 2,408 | 2,934 | 3,037 | 3,379 | 4,058 |
| Operating Profit | 505 | 594 | 691 | 658 | 567 | 683 | 1,001 | 933 | 808 | 1,172 | 1,269 | 1,395 |
| OPM % | 34% | 34% | 35% | 31% | 28% | 26% | 35% | 28% | 22% | 28% | 27% | 26% |
| Other Income + | 8 | 14 | 20 | 24 | 21 | 88 | 24 | 112 | 74 | 85 | 85 | 172 |
| Interest | 6 | 5 | 1 | 0 | 1 | 12 | 8 | 10 | 6 | 7 | 21 | 16 |
| Depreciation | 52 | 44 | 61 | 60 | 72 | 96 | 116 | 125 | 131 | 135 | 144 | 173 |
| Profit before tax | 456 | 559 | 648 | 623 | 514 | 664 | 900 | 909 | 745 | 1,114 | 1,189 | 1,378 |
| Tax % | 32% | 26% | 22% | 25% | 25% | 30% | 27% | 22% | 21% | 27% | 23% | 23% |
| Net Profit + | 310 | 416 | 507 | 469 | 387 | 468 | 654 | 713 | 588 | 816 | 920 | 1,056 |
| EPS in Rs | 23.47 | 31.49 | 38.40 | 35.50 | 29.56 | 35.73 | 50.38 | 55.63 | 45.89 | 63.70 | 73.68 | 84.52 |
| Dividend Payout % | 17% | 17% | 23% | 0% | 20% | 24% | 13% | 11% | 15% | 79% | 38% | 0% |
Financials of Ajanta Pharma Ltd
Capital structure and asset base
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 18 | 18 | 18 | 18 | 18 | 18 | 17 | 17 | 25 | 25 | 25 | 25 |
| Reserves | 823 | 1,173 | 1,550 | 2,024 | 2,228 | 2,581 | 2,978 | 3,247 | 3,363 | 3,542 | 3,765 | 4,502 |
| Borrowings + | 72 | 81 | 1 | 2 | 36 | 75 | 31 | 25 | 36 | 35 | 47 | 260 |
| Other Liabilities + | 233 | 207 | 254 | 383 | 383 | 619 | 702 | 711 | 1,159 | 927 | 1,067 | 1,368 |
| Total Liabilities | 1,146 | 1,479 | 1,823 | 2,426 | 2,664 | 3,293 | 3,729 | 4,000 | 4,582 | 4,530 | 4,904 | 6,155 |
| Fixed Assets + | 288 | 451 | 589 | 1,053 | 1,178 | 1,472 | 1,541 | 1,512 | 1,496 | 1,479 | 1,762 | 1,867 |
| CWIP | 170 | 240 | 339 | 61 | 262 | 132 | 108 | 153 | 209 | 256 | 176 | 258 |
| Investments | 60 | 86 | 182 | 190 | 78 | 79 | 176 | 147 | 535 | 349 | 464 | 588 |
| Other Assets + | 629 | 703 | 713 | 1,122 | 1,147 | 1,610 | 1,904 | 2,188 | 2,341 | 2,446 | 2,502 | 3,441 |
| Total Assets | 1,146 | 1,479 | 1,823 | 2,426 | 2,664 | 3,293 | 3,729 | 4,000 | 4,582 | 4,530 | 4,904 | 6,155 |
Financials of Ajanta Pharma Ltd
Operating, investing and financing cash movement
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 279 | 326 | 609 | 281 | 375 | 457 | 576 | 562 | 792 | 785 | 1,157 | 529 |
| Cash from Investing Activity + | -158 | -209 | -383 | -256 | -223 | -224 | -282 | -74 | -560 | 65 | -377 | -429 |
| Cash from Financing Activity + | -105 | -117 | -202 | -0 | -147 | -129 | -318 | -460 | -108 | -1,051 | -733 | -168 |
| Net Cash Flow | 16 | -0 | 24 | 25 | 4 | 104 | -24 | 28 | 124 | -201 | 47 | -68 |
| Free Cash Flow | 176 | 29 | 313 | 19 | 32 | 228 | 417 | 431 | 618 | 646 | 840 | 169 |
| CFO/OP | 84% | 82% | 110% | 64% | 87% | 89% | 81% | 86% | 117% | 94% | 117% | 64% |
Financials of Ajanta Pharma Ltd
Working capital efficiency and return ratios
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 64 | 78 | 59 | 79 | 82 | 109 | 93 | 111 | 103 | 108 | 93 | 124 |
| Inventory Days | 159 | 180 | 186 | 315 | 415 | 276 | 434 | 347 | 283 | 283 | 308 | 289 |
| Days Payable | 109 | 128 | 157 | 224 | 214 | 202 | 212 | 143 | 147 | 159 | 155 | 168 |
| Cash Conversion Cycle | 114 | 130 | 88 | 170 | 282 | 184 | 315 | 315 | 240 | 233 | 246 | 246 |
| Working Capital Days | 56 | 78 | 65 | 103 | 113 | 108 | 126 | 140 | 83 | 119 | 97 | 148 |
| ROCE % | 57% | 52% | 46% | 34% | 24% | 27% | 32% | 29% | 23% | 32% | 32% | 32% |